Rutgers Entrepreneurs: Meet Andrew Brooks, CEO of Infinity Biologix, Rutgers’ $44M Spinout and First To Market COVID-19 Saliva Test

Join the conversation with Andrew Brooks, CEO of Infinity Biologix, about the evolution of Rutgers’ RUCDR Infinite Biologics laboratory, the experience of launching the $44m spinout from the university, and developing the first COVID-19 saliva test to receive Emergency Use Authorization from the FDA in April 2020.

The event will be hosted by Pavita Howe, Director of Entrepreneurship Partnerships at Rutgers Corporate Engagement Center. 

Organized by:  Rutgers Entrepreneurs – Corporate Engagement Center

Co-sponsored by:  Rutgers University Alumni Association